Targeted Oncology Identify opportunities to engage Sunesis around their BTK inhibitor program, particularly vecabrutinib (SNS-062) for ibrutinib-resistant CLL, and explore partnerships or co-development options with oncology-focused CROs, contract manufacturability, or companion diagnostics to accelerate proof-of-concept studies.

Small Biotech Partnerships Position Sunesis as a potential partner for mid-stage trial support, given their lean team (11-50 employees) and focus on translational and clinical science; offer lightweight clinical trial execution services, data management, and regulatory consulting tailored to small biotech timelines.

External M&A Readiness Monitor Sunesis’ merger activity with Viracta and related fiduciary concerns as a signal of strategic pivots; present opportunities in asset acquisition, licensing, or co-financing of late-stage programs for oncology indications aligned with their pipeline.

Diversified Revenue Levers Propose collaborations beyond their lead BTK program, such as oncology biomarkers, companion diagnostics, or research collaborations using their hematologic/solid tumor focus to build a diversified portfolio and potential revenue streams.

Operational Efficiencies Offer scalable, cost-efficient solutions tailored for smaller biotechs—cloud-based analytics, low-burn clinical data management, and integrated analytics (leveraging their tech stack) to accelerate decision-making and de-risk development milestones.